Cargando…
Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19
Background and objectives: The COVID-19 pandemic continues worldwide, and there is no effective treatment to treat it. Chinese medicine is considered the recommended treatment for COVID-19 in China. This study aimed to examine the effectiveness of tetrandrine in treating COVID-19, which is originall...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503147/ https://www.ncbi.nlm.nih.gov/pubmed/36143871 http://dx.doi.org/10.3390/medicina58091194 |
_version_ | 1784795890682167296 |
---|---|
author | Chen, Shiyin Liu, Yiran Ge, Juan Yin, Jianzhong Shi, Ting Ntambara, James Cheng, Zhounan Chu, Minjie Gu, Hongyan |
author_facet | Chen, Shiyin Liu, Yiran Ge, Juan Yin, Jianzhong Shi, Ting Ntambara, James Cheng, Zhounan Chu, Minjie Gu, Hongyan |
author_sort | Chen, Shiyin |
collection | PubMed |
description | Background and objectives: The COVID-19 pandemic continues worldwide, and there is no effective treatment to treat it. Chinese medicine is considered the recommended treatment for COVID-19 in China. This study aimed to examine the effectiveness of tetrandrine in treating COVID-19, which is originally derived from Chinese medicine. Materials and Methods: A total of 60 patients, categorized into three types (mild, moderate, severe), from Daye Hospital of Chinese Medicine with a diagnosis of COVID-19 were included in this study. Demographics, medical history, treatment, and results were collected. We defined two main groups according to the clinical outcome between improvement and recovery. All underlying factors including clinical outcomes were assessed in the total number of COVID-19 patients and moderate-type patients. Results: In a total of 60 patients, there were significant differences in the clinical outcome underlying treatment with antibiotics, tetrandrine, and arbidol (p < 0.05). When the comparison was limited to the moderate type, treatment with tetrandrine further increased recovery rate (p = 0.007). However, the difference disappeared, and no association was indicated between the clinical outcome and the treatment with and without antibiotic (p = 0.224) and arbidol (p = 0.318) in the moderate-type patients. In all-type and moderate-type patients, tetrandrine improved the rate of improvement in cough and fatigue on day 7 (p < 0.05). Conclusions: Tetrandrine may improve clinical outcome in COVID-19 patientsand could be a promising potential natural antiviral agent for the prevention and treatment of COVID-19. |
format | Online Article Text |
id | pubmed-9503147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95031472022-09-24 Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19 Chen, Shiyin Liu, Yiran Ge, Juan Yin, Jianzhong Shi, Ting Ntambara, James Cheng, Zhounan Chu, Minjie Gu, Hongyan Medicina (Kaunas) Article Background and objectives: The COVID-19 pandemic continues worldwide, and there is no effective treatment to treat it. Chinese medicine is considered the recommended treatment for COVID-19 in China. This study aimed to examine the effectiveness of tetrandrine in treating COVID-19, which is originally derived from Chinese medicine. Materials and Methods: A total of 60 patients, categorized into three types (mild, moderate, severe), from Daye Hospital of Chinese Medicine with a diagnosis of COVID-19 were included in this study. Demographics, medical history, treatment, and results were collected. We defined two main groups according to the clinical outcome between improvement and recovery. All underlying factors including clinical outcomes were assessed in the total number of COVID-19 patients and moderate-type patients. Results: In a total of 60 patients, there were significant differences in the clinical outcome underlying treatment with antibiotics, tetrandrine, and arbidol (p < 0.05). When the comparison was limited to the moderate type, treatment with tetrandrine further increased recovery rate (p = 0.007). However, the difference disappeared, and no association was indicated between the clinical outcome and the treatment with and without antibiotic (p = 0.224) and arbidol (p = 0.318) in the moderate-type patients. In all-type and moderate-type patients, tetrandrine improved the rate of improvement in cough and fatigue on day 7 (p < 0.05). Conclusions: Tetrandrine may improve clinical outcome in COVID-19 patientsand could be a promising potential natural antiviral agent for the prevention and treatment of COVID-19. MDPI 2022-09-01 /pmc/articles/PMC9503147/ /pubmed/36143871 http://dx.doi.org/10.3390/medicina58091194 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Shiyin Liu, Yiran Ge, Juan Yin, Jianzhong Shi, Ting Ntambara, James Cheng, Zhounan Chu, Minjie Gu, Hongyan Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19 |
title | Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19 |
title_full | Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19 |
title_fullStr | Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19 |
title_full_unstemmed | Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19 |
title_short | Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19 |
title_sort | tetrandrine treatment may improve clinical outcome in patients with covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503147/ https://www.ncbi.nlm.nih.gov/pubmed/36143871 http://dx.doi.org/10.3390/medicina58091194 |
work_keys_str_mv | AT chenshiyin tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT liuyiran tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT gejuan tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT yinjianzhong tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT shiting tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT ntambarajames tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT chengzhounan tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT chuminjie tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 AT guhongyan tetrandrinetreatmentmayimproveclinicaloutcomeinpatientswithcovid19 |